Inhibition of brain-dependent nitric oxide (NO) over-production by isoform-selective NO synthase (NOS) inhibitors
John Andrews, PhD, NeurAxon, Toronto, Ontario, Canada
Development of HSF1 effectors as Parkinson's disease therapeutics
William Janzen, PhD, and Maria Sippola-Thiele, PhD, Chaperone Therapeutics, Durham, North Carolina
Optimizing metalloporphryins for clinical development
Manish Patel, PhD, University of Colorado, Denver, Colorado
Optimization of alpha synuclein 5'UTR directed translation blockers as novel drugs for Parkinson's disease
Jack Rogers, PhD, Mental Health Research Institute of Victoria, Melbourne, Australia
Cerium oxide nanoparticles in treatment of Parkinson's disease
Beverly Rzigalinski, PhD, Virginia College of Osteopathic Medicine, Blacksburg, Virginia
Novel JNK inhibitors as therapeutic agents for Parkinson's disease
Bobby Thomas, PhD, Weill Medical College of Cornell University, New York, New York and Maurizio Pellecchia, PhD, Burnham Institute for Medical Research, La Jolla, California

stakeholders making decisions for us.......it looks good i guess.......